The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Caelyx

2.0 milligram(s)/millilitre Concentrate for Susp for Inf

Janssen-Cilag International NVEU/1/96/011/002

Main Information

Trade NameCaelyx
Active SubstancesDOXORUBICIN HYDROCHLORIDE
Strength2.0 milligram(s)/millilitre
Dosage FormConcentrate for Susp for Inf
Licence HolderJanssen-Cilag International NV
Licence NumberEU/1/96/011/002

Group Information

ATC CodeL01DB Anthracyclines and related substances
L01DB01 doxorubicin

Status

Authorised/WithdrawnAuthorised
Licence Issued21/06/1996
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).
Marketing Status

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back